

# THE LANCET Oncology

## Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Brenner MK, Gottschalk S, Leen AM, Vera JF. Is cancer gene therapy an empty suit? *Lancet Oncol* 2013; **13**: e447–56.

<b>Haematological malignant diseases</b>	<b>In vitro</b>	<b>Animal data</b>	<b>Clinical data</b>
CAR-CD19 <sup>1-12</sup>	X	X	X
CAR-CD20 <sup>6,13-16</sup>	X	X	X
CAR-CD30 <sup>17-19</sup>	X	X	Ongoing
CAR-Kappa <sup>20</sup>	X	X	Ongoing
CAR-CD70 <sup>21</sup>	X	X	
CAR-NKG2D ligands <sup>22</sup>	X	X	
<b>Solid tumours</b>	<b>In vitro</b>	<b>Animal data</b>	<b>Clinical data</b>
CAR-GD2 (neuroblastoma) <sup>23-25</sup>	X	X	X
CAR-HER2 (colorectal/lung/sarcoma/glioblastoma) <sup>26-33</sup>	X	X	X
CAR-FBP (ovarian) <sup>34-37</sup>	X	X	X
CAR-CD171 (neuroblastoma) <sup>38,39</sup>	X		X
CAR-CAIX (kidney) <sup>40,41</sup>	X		X
CAR-PSMA (prostate) <sup>42,43</sup>	X	X	Ongoing
CAR-IL13R $\alpha$ 2 (glioblastoma) <sup>44-47</sup>	X	X	Ongoing
CAR-KDR (vasculature/melanoma) <sup>48-50</sup>	X	X	Ongoing
CAR-EGFRvIII (glioblastoma) <sup>51,52</sup>	X		Ongoing
CAR-Mesothelin (pleural mesothelioma/breast) <sup>53-56</sup>	X	X	Ongoing
CAR-EphA2 (glioblastoma) <sup>57</sup>	X	X	
CAR-CD44 v6/v7 (cervical) <sup>58,59</sup>	X	X	
CAR-TAG72 (colon) <sup>60,61</sup>	X	X	
CAR-Lewis-Y (breast/ovarian/pancreatic) <sup>62-64</sup>	X	X	
CAR-Muc1 (ovarian/breast/prostate) <sup>65-67</sup>	X	X	
CAR-IL11R $\alpha$ (osteosarcoma) <sup>68</sup>	X	X	
CAR-FAR (rhabdomyosarcoma) <sup>69</sup>	X		
CAR-NCAM (colorectal) <sup>70</sup>	X		
CAR-EGP2 (carcinomas) <sup>71,72</sup>	X		
CAR-EGP40 (colon) <sup>73</sup>	X		
CAR-CEA (colorectal) <sup>74-77</sup>	X		
CAR-ERBB3/4 (breast/ovarian) <sup>78,79</sup>	X		
CAR-GD3 (melanoma) <sup>80</sup>	X		
CAR-PSCA (prostate/pancreatic) <sup>81,82</sup>	X		
CAR-HLA-A1+MAGE1 (melanoma) <sup>83,84</sup>	X		

**Table: Chimeric antigen receptors in (or approaching) clinical development for cancer**

## Supplemental references

- 1 Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. *Blood* 2012; **119**: 2709–20.
- 2 Brentjens RJ, Rivière I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. *Blood* 2011; **118**: 4817–28.
- 3 Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T Cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. *Sci Transl Med* 2013; **5**: 177ra38.
- 4 Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *N Engl J Med* 2013; **368**: 1509–18.
- 5 Cooper LJ, Al Kadhimi Z, Serrano LM, et al. Enhanced antilymphoma efficacy of CD19-redredirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. *Blood*. 2005; **105**: 1622-1631.
- 6 Jensen MC, Popplewell L, Cooper LJ, et al. Anti-Transgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Re-directed T Cells in Humans. *Biol Blood Marrow Transplant*. 2010;
- 7 Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. *J Clin Invest*. 2011; **121**: 1822-1826.
- 8 Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. *Blood*. 2012; **119**: 2709-2720.
- 9 Brentjens R, Riviere I, Hollyman D, et al. Unexpected Toxicity of Cyclophosphamide Followed by Adoptively Transferred CD19-Targeted T cells in a Patient with Bulky CLL. *Molecular Therapy*. 2009; **17**: S157.
- 10 Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. *Nat Med*. 2003; **9**: 279-286.
- 11 Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *N Engl J Med*. 2011; **365**: 725-733.
- 12 Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. *Sci Transl Med*. 2011; **3**: 95ra73.
- 13 Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. *Blood*. 2008; **112**: 2261-2271.

- 14 Wang J, Jensen M, Lin Y, et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. *Hum Gene Ther.* 2007; **18**: 712-725.
- 15 Wang J, Press OW, Lindgren CG, et al. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. *Mol Ther.* 2004; **9**: 577-586.
- 16 Jensen M, Tan G, Forman S, Wu AM, Raubitschek A. CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. *Biol Blood Marrow Transplant.* 1998; **4**: 75-83.
- 17 Di Stasi A, De Angelis B, Rooney CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. *Blood.* 2009; **113**: 6392-6402.
- 18 Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. *Blood.* 2007; **110**: 2620-2630.
- 19 Hombach A, Heuser C, Sircar R, et al. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. *Cancer Res.* 1998; **58**: 1116-1119.
- 20 Vera J, Savoldo B, Vigouroux S, et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. *Blood.* 2006; **108**: 3890-3897.
- 21 Shaffer DR, Savoldo B, Yi Z, et al. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. *Blood.* 2011; **117**: 4304-4314.
- 22 Barber A, Zhang T, Megli CJ, Wu J, Meehan KR, Sentman CL. Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. *Exp Hematol.* 2008; **36**: 1318-1328.
- 23 Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. *Nat Med.* 2008; **14**: 1264-1270.
- 24 Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. *Blood.* 2011; **118**: 6050-6056.
- 25 Rossig C, Bollard CM, Nuchtern JG, Merchant DA, Brenner MK. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes 5. *Int J Cancer.* 2001; **94**: 228-236.
- 26 Zhao Y, Wang QJ, Yang S, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. *J Immunol.* 2009; **183**: 5563-5574.
- 27 Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. *Mol Ther.* 2010; **18**: 843-851.

- 28 Pinthus JH, Waks T, Malina V, et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. *J Clin Invest.* 2004; **114**: 1774-1781.
- 29 Teng MW, Kershaw MH, Moeller M, Smyth MJ, Darcy PK. Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. *Hum Gene Ther.* 2004; **15**: 699-708.
- 30 Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. *J Immunol.* 1993; **151**: 6577-6582.
- 31 Ahmed N, Salsman VS, Yvon E, et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. *Mol Ther.* 2009; **17**: 1779-1787.
- 32 Ahmed N, Salsman VS, Kew Y, et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. *Clin Cancer Res.* 2010; **16**: 474-485.
- 33 Moritz D, Wels W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. *Proc Natl Acad Sci U S A.* 1994; **91**: 4318-4322.
- 34 Hwu P, Shafer GE, Treisman J, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. *J Exp Med.* 1993; **178**: 361-366.
- 35 Kershaw MH, Westwood JA, Hwu P. Dual-specific T cells combine proliferation and antitumor activity. *Nat Biotechnol.* 2002; **20**: 1221-1227.
- 36 Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. *Clin Cancer Res.* 2006; **12**: 6106-6115.
- 37 Hwu P, Yang JC, Cowherd R, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T cell receptor genes. *Cancer Res.* 1995; **55**: 3369-3373.
- 38 Gonzalez S, Naranjo A, Serrano LM, Chang WC, Wright CL, Jensen MC. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma. *J Gene Med.* 2004; **6**: 704-711.
- 39 Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor redirected cytolytic T lymphocyte clones in patients with neuroblastoma. *Mol Ther.* 2007; **15**: 825-833.
- 40 Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. *J Clin Oncol* 2006; **24**: e20–e22.
- 41 Weijtens ME, Willemsen RA, van Krimpen BA, Bolhuis RL. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules. *Int J Cancer.* 1998; **77**: 181-187.
- 42 Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. *Nat Biotechnol.* 2002; **20**: 70-75.

- 43 Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. *Neoplasia*. 1999; **1**: 123-127.
- 44 Brown CE, Starr R, Aguilar B, et al. Stem-like tumor initiating cells isolated from IL13Ralpha2-expressing gliomas are targeted and killed by IL13-zetakine redirected T cells. *Clin Cancer Res*. 2012;
- 45 Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. *Cancer Res*. 2004; **64**: 9160-9166.
- 46 Kong S, Sengupta S, Tyler B, et al. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. *Clin Cancer Res*. 2012; **18**: 5949-5960.
- 47 Yaghoubi SS, Jensen MC, Satyamurthy N, et al. Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. *Nat Clin Pract Oncol*. 2009; **6**: 53-58.
- 48 Niederman TM, Ghogawala Z, Carter BS, Tompkins HS, Russell MM, Mulligan RC. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. *Proc Natl Acad Sci U S A*. 2002; **99**: 7009-7014.
- 49 Chinnasamy D, Yu Z, Theoret MR, et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. *J Clin Invest*. 2010; **120**: 3953-3968.
- 50 Kershaw MH, Westwood JA, Zhu Z, Witte L, Libutti SK, Hwu P. Generation of gene-modified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature. *Hum Gene Ther*. 2000; **11**: 2445-2452.
- 51 Morgan RA, Johnson LA, Davis JL, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. *Hum Gene Ther*. 2012; **23**: 1043-1053.
- 52 Bullain SS, Sahin A, Szentirmai O, et al. Genetically engineered T cells to target EGFRvIII expressing glioblastoma. *J Neurooncol*. 2009; **94**: 373-382.
- 53 Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. *Proc Natl Acad Sci U S A*. 2009; **106**: 3360-3365.
- 54 Moon EK, Carpenito C, Sun J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. *Clin Cancer Res*. 2011; **17**: 4719-4730.
- 55 Zhao Y, Moon E, Carpenito C, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. *Cancer Res*. 2010; **70**: 9053-9061.
- 56 Tchou J, Wang LC, Selven B, et al. Mesothelin, a novel immunotherapy target for triple negative breast cancer. *Breast Cancer Res Treat*. 2012; **133**: 799-804.

- 57 Chow KK, Naik S, Kakarla S, et al. T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma. *Mol Ther.* 2013; **21**: 629-637.
- 58 Hekele A, Dall P, Moritz D, et al. Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera. *Int J Cancer.* 1996; **68**: 232-238.
- 59 Dall P, Herrmann I, Durst B, et al. In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells. *Cancer Immunol Immunother.* 2005; **54**: 51-60.
- 60 Hombach A, Heuser C, Sircar R, et al. T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. *Gastroenterology.* 1997; **113**: 1163-1170.
- 61 McGuinness RP, Ge Y, Patel SD, et al. Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor [see comments]. *Hum Gene Ther.* 1999; **10**: 165-173.
- 62 Westwood JA, Smyth MJ, Teng MW, et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. *Proc Natl Acad Sci U S A.* 2005; **102**: 19051-19056.
- 63 Mezzanzanica D, Canevari S, Mazzoni A, et al. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells. *Cancer Gene Ther.* 1998; **5**: 401-407.
- 64 Peinert S, Prince HM, Guru PM, et al. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. *Gene Ther.* 2010; **17**: 678-686.
- 65 Maher J, Wilkie S. CAR mechanics: driving T cells into the MUC of cancer. *Cancer Res.* 2009; **69**: 4559-4562.
- 66 Wilkie S, van Schalkwyk MC, Hobbs S, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. *J Clin Immunol.* 2012; **32**: 1059-1070.
- 67 Wilkie S, Picco G, Foster J, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. *J Immunol.* 2008; **180**: 4901-4909.
- 68 Huang G, Yu L, Cooper LJ, Hollomon M, Huls H, Kleinerman ES. Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. *Cancer Res.* 2012; **72**: 271-281.
- 69 Gattenlohner S, Marx A, Markfort B, et al. Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor. *Cancer Res.* 2006; **66**: 24-28.
- 70 Gilham DE, O'Neil A, Hughes C, et al. Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. *J Immunother.* 2002; **25**: 139-151.
- 71 Meier R, Golovko D, Tavri S, et al. Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging. *Magn Reson Med.* 2011; **65**: 756-763.

- 72 Ren-Heidenreich L, Mordini R, Hayman GT, Siebenlist R, LeFever A. Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis. *Cancer Immunol Immunother.* 2002; **51**: 417-423.
- 73 Daly T, Royal RE, Kershaw MH, et al. Recognition of human colon cancer by T cells transduced with a chimeric receptor gene. *Cancer Gene Ther.* 2000; **7**: 284-291.
- 74 Nolan KF, Yun CO, Akamatsu Y, et al. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. *Clin Cancer Res.* 1999; **5**: 3928-3941.
- 75 Darcy PK, Kershaw MH, Trapani JA, Smyth MJ. Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma. *Eur J Immunol.* 1998; **28**: 1663-1672.
- 76 Haynes NM, Trapani JA, Teng MW, et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. *J Immunol.* 2002; **169**: 5780-5786.
- 77 Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. *Mol Ther.* 2011; **19**: 620-626.
- 78 Muniappan A, Banapour B, Lebkowski J, Talib S. Ligand-mediated cytolysis of tumor cells: use of heregulin-zeta chimeras to redirect cytotoxic T lymphocytes. *Cancer Gene Ther.* 2000; **7**: 128-134.
- 79 Altenschmidt U, Kahl R, Moritz D, et al. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. *Clin Cancer Res.* 1996; **2**: 1001-1008.
- 80 Yun CO, Nolan KF, Beecham EJ, Reisfeld RA, Junghans RP. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. *Neoplasia.* 2000; **2**: 449-459.
- 81 Morgenroth A, Cartellieri M, Schmitz M, et al. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. *Prostate.* 2007; **67**: 1121-1131.
- 82 Katari UL, Keirnan JM, Worth AC, et al. Engineered T cells for pancreatic cancer treatment. *HPB (Oxford).* 2011; **13**: 643-650.
- 83 Willemsen RA, Debets R, Hart E, Hoogenboom HR, Bolhuis RL, Chames P. A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. *Gene Ther.* 2001; **8**: 1601-1608.
- 84 Willemsen RA, Ronteltap C, Chames P, Debets R, Bolhuis RL. T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. *J Immunol.* 2005; **174**: 7853-7858.